152 related articles for article (PubMed ID: 11504091)
1. Effect of corrections for blood glucose and body size on [18F]FDG PET standardised uptake values in lung cancer.
Hallett WA; Marsden PK; Cronin BF; O'Doherty MJ
Eur J Nucl Med; 2001 Jul; 28(7):919-22. PubMed ID: 11504091
[TBL] [Abstract][Full Text] [Related]
2. Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues.
Paquet N; Albert A; Foidart J; Hustinx R
J Nucl Med; 2004 May; 45(5):784-8. PubMed ID: 15136627
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of various corrections to the standardized uptake value for diagnosis of pulmonary malignancy.
Menda Y; Bushnell DL; Madsen MT; McLaughlin K; Kahn D; Kernstine KH
Nucl Med Commun; 2001 Oct; 22(10):1077-81. PubMed ID: 11567179
[TBL] [Abstract][Full Text] [Related]
4. Correlation of Glut-1 glucose transporter expression with.
Higashi K; Ueda Y; Sakurai A; Wang XM; Xu L; Murakami M; Seki H; Oguchi M; Taki S; Nambu Y; Tonami H; Katsuda S; Yamamoto I
Eur J Nucl Med; 2000 Dec; 27(12):1778-85. PubMed ID: 11189940
[TBL] [Abstract][Full Text] [Related]
5. Influence of N-butylscopolamine on SUV in FDG PET of the bowel.
Sanghera B; Emmott J; Wellsted D; Chambers J; Wong WL
Ann Nucl Med; 2009 Jul; 23(5):471-8. PubMed ID: 19444552
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional clinical PET in lung cancer: validation and practical strategies.
Calvo R; Martí-Climent JM; Richter JA; Peñuelas I; Crespo-Jara A; Villar LM; García-Velloso MJ
J Nucl Med; 2000 Mar; 41(3):439-48. PubMed ID: 10716316
[TBL] [Abstract][Full Text] [Related]
7. Fluoro-deoxy-glucose positron emission tomography for evaluation of indeterminate lung nodules: assigning a probability of malignancy may be preferable to binary readings.
Kim SC; Machac J; Krynyckyi BR; Knesaurek K; Krellenstein D; Schultz B; Gribetz A; DePalo L; Teirstein A; Kim CK
Ann Nucl Med; 2008 Apr; 22(3):165-70. PubMed ID: 18498030
[TBL] [Abstract][Full Text] [Related]
8. Does diabetes affect [(18)F]FDG standardised uptake values in lung cancer?
Gorenberg M; Hallett WA; O'Doherty MJ
Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1324-7. PubMed ID: 12271414
[TBL] [Abstract][Full Text] [Related]
9. Test-Retest Variability in Lesion SUV and Lesion SUR in
Hofheinz F; Apostolova I; Oehme L; Kotzerke J; van den Hoff J
J Nucl Med; 2017 Nov; 58(11):1770-1775. PubMed ID: 28473598
[TBL] [Abstract][Full Text] [Related]
10. Measuring [(18)F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods.
Krak NC; van der Hoeven JJ; Hoekstra OS; Twisk JW; van der Wall E; Lammertsma AA
Eur J Nucl Med Mol Imaging; 2003 May; 30(5):674-81. PubMed ID: 12640556
[TBL] [Abstract][Full Text] [Related]
11. Quantification of tumour (18) F-FDG uptake: Normalise to blood glucose or scale to liver uptake?
Keramida G; Dizdarevic S; Bush J; Peters AM
Eur Radiol; 2015 Sep; 25(9):2701-8. PubMed ID: 25899414
[TBL] [Abstract][Full Text] [Related]
12. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
13. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
[TBL] [Abstract][Full Text] [Related]
14. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET.
Stahl A; Ott K; Schwaiger M; Weber WA
Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1471-8. PubMed ID: 15257418
[TBL] [Abstract][Full Text] [Related]
15. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET.
Minn H; Zasadny KR; Quint LE; Wahl RL
Radiology; 1995 Jul; 196(1):167-73. PubMed ID: 7784562
[TBL] [Abstract][Full Text] [Related]
16. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
17. Regional 2-[18F]fluoro-2-deoxy-D-glucose uptake varies in normal lung.
Miyauchi T; Wahl RL
Eur J Nucl Med; 1996 May; 23(5):517-23. PubMed ID: 8698055
[TBL] [Abstract][Full Text] [Related]
18. Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning.
Hong R; Halama J; Bova D; Sethi A; Emami B
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):720-6. PubMed ID: 17293230
[TBL] [Abstract][Full Text] [Related]
19. Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study.
Hara T; Kosaka N; Suzuki T; Kudo K; Niino H
Chest; 2003 Sep; 124(3):893-901. PubMed ID: 12970014
[TBL] [Abstract][Full Text] [Related]
20. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction.
Zasadny KR; Wahl RL
Radiology; 1993 Dec; 189(3):847-50. PubMed ID: 8234714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]